Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer

被引:15
|
作者
Kenmotsu, Hirotsugu [1 ]
Ohde, Yasuhisa [2 ]
Wakuda, Kazushige [1 ]
Nakashima, Kazuhisa [1 ]
Omori, Shota [1 ]
Ono, Akira [1 ]
Naito, Tateaki [1 ]
Murakami, Haruyasu [1 ]
Kojima, Hideaki [2 ]
Takahashi, Shoji [2 ]
Isaka, Mitsuhiro [2 ]
Endo, Masahiro [3 ]
Takahashi, Toshiaki [1 ]
机构
[1] Shizuoka Canc Ctr, Div Thorac Oncol, 1007 Shimonagakubo, Nagaizumi, Shizuoka 4118777, Japan
[2] Shizuoka Canc Ctr, Div Thorac Surg, 1007 Shimonagakubo, Nagaizumi, Shizuoka 4118777, Japan
[3] Shizuoka Canc Ctr, Div Diagnost Radiol, 1007 Shimonagakubo, Nagaizumi, Shizuoka 4118777, Japan
关键词
Non-small-cell lung cancer; Adjuvant chemotherapy; Cisplatin; Vinorelbine; Survival; PHASE-II; STAGE-II; GEFITINIB; PROGNOSIS; REGISTRY; PLACEBO; TRIAL;
D O I
10.1007/s00280-017-3400-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite the efficacy of postoperative adjuvant cisplatin (CDDP)-based chemotherapy for patients who have undergone surgical resection of non-small cell lung cancer (NSCLC), few reports have presented survival data for Asian patients treated with adjuvant chemotherapy involving a combination of CDDP and vinorelbine (VNR). This study was performed to evaluate the survival of patients with NSCLC who received postoperative adjuvant chemotherapy comprising CDDP + VNR. We retrospectively evaluated patients with NSCLC who received adjuvant chemotherapy comprising CDDP + VNR at the Shizuoka Cancer Center between February 2006 and October 2011. One hundred patients who underwent surgical resection of NSCLC were included in this study. The patients' characteristics were as follows: median age 63 years (range 36-74 years), female 34%, never-smokers 20%, and non-squamous NSCLC 73%. Pathological stages IIA, IIB, and IIIA were observed in 31, 22, and 47% of patients, respectively. The 5- and 2-year overall survival rates were 73 and 93%, respectively. The 5- and 2-year relapse-free survival rates were 53 and 62%, respectively. Univariate analysis of prognostic factors showed that patient characteristics (sex, histology, and pathological stage) and CDDP dose intensity were not significantly associated with survival. In 48 patients who developed NSCLC recurrence, the 5-year survival rate after recurrence was 29%, and the median survival time after recurrence was 37 months. Our results suggest that the prognosis after surgical resection of NSCLC and adjuvant chemotherapy comprising CDDP + VNR might be improving compared with previous survival data of adjuvant chemotherapy for NSCLC.
引用
收藏
页码:609 / 614
页数:6
相关论文
共 50 条
  • [1] Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer
    Hirotsugu Kenmotsu
    Yasuhisa Ohde
    Kazushige Wakuda
    Kazuhisa Nakashima
    Shota Omori
    Akira Ono
    Tateaki Naito
    Haruyasu Murakami
    Hideaki Kojima
    Shoji Takahashi
    Mitsuhiro Isaka
    Masahiro Endo
    Toshiaki Takahashi
    [J]. Cancer Chemotherapy and Pharmacology, 2017, 80 : 609 - 614
  • [2] Cisplatin plus vinorelbine chemotherapy for non-small cell lung cancer
    Pereira, JR
    Gampel, O
    Martins, SJ
    Ikari, FK
    Nikaedo, SM
    Paschoalini, M
    [J]. 17TH INTERNATIONAL CANCER CONGRESS, VOL 1 AND 2, 1998, : 643 - 646
  • [3] Adjuvant Chemotherapy After Complete Resection of Non-Small Cell Lung Cancer
    Laack, E.
    Bokemeyer, C.
    Hossfeld, D. K.
    [J]. DEUTSCHES ARZTEBLATT INTERNATIONAL, 2008, 105 (14): : 249 - 254
  • [4] Efficacy of cisplatin plus vinorelbine adjuvant chemotherapy with split-dose administration of cisplatin after complete resection of stage II-IIIA non-small cell lung cancer
    Funaguchi, Norihiko
    Iihara, Hirotoshi
    Kaito, Daizo
    Gomyo, Takenori
    Sasaki, Yuka
    Yanase, Komei
    Endo, Junki
    Ito, Fumitaka
    Hirose, Chiemi
    Ohno, Yasushi
    Okura, Hiroyuki
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2022, 16 (04)
  • [5] Adjuvant Chemotherapy After Complete Resection of Non-Small Cell Lung Cancer Reply
    Laack, Eckart
    [J]. DEUTSCHES ARZTEBLATT INTERNATIONAL, 2008, 105 (25): : 457 - 457
  • [6] Real life adjuvant chemotherapy uptake and survival in patients with non-small cell lung cancer after complete resection
    Kolek, Vitezslav
    Losse, Stanislav
    Kultan, Juraj
    Jakubec, Petr
    Jaromir, Zatloukal
    Sova, Milan
    Szkorupa, Marek
    Neoral, Cestmir
    Skarda, Josef
    Tichy, Tomas
    Kolar, Zdenek
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (09) : 1687 - 1694
  • [7] Adjuvant chemotherapy after complete resection in non-small-cell lung cancer
    Wada, H
    Hitomi, S
    Teramatsu, T
    Ikeda, S
    Okada, Y
    Kusakawa, M
    Soejima, R
    Teramoto, S
    Tomita, M
    Hirakawa, A
    Maeda, M
    Yamamoto, K
    Monden, Y
    Kimura, I
    Ohta, M
    Ayabe, H
    Ito, M
    Kato, H
    Genka, K
    Shimizu, N
    Tsubota, N
    Nakamoto, K
    Namikawa, S
    Matsubara, Y
    Okimoto, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) : 1048 - 1054
  • [8] Survival data of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected NSCLC
    Kenmotsu, Hirotsugu
    Ohde, Yasuhisa
    Wakuda, Kazushige
    Nakashima, Kazuhisa
    Omori, Shota
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Endo, Masahiro
    Takahashi, Toshiaki
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [9] Feasibility of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected non-small-cell lung cancer: A retrospective study in Japan
    Kenmotsu, Hirotsugu
    Ohde, Yasuhisa
    Shukuya, Takehito
    Eida, Hirofumi
    Akamatsu, Hiroaki
    Ono, Akira
    Nakamura, Yukiko
    Tsuya, Asuka
    Kaira, Kyoichi
    Naito, Tateaki
    Murakami, Haruyasu
    Takahashi, Toshiaki
    Maniwa, Tomohiro
    Isaka, Mitsuhiro
    Endo, Masahiro
    Kondo, Haruhiko
    Yamamoto, Nobuyuki
    [J]. RESPIRATORY INVESTIGATION, 2012, 50 (04) : 157 - 161
  • [10] Split-dose Cisplatin and Vinorelbine as Adjuvant Chemotherapy for Completely Resected Non-small Cell Lung Cancer
    Hirai, Fumihiko
    Seto, Takashi
    Shimokawa, Mototsugu
    Inamasu, Eiko
    Toyozawa, Ryo
    Toyokawa, Gouji
    Yoshida, Tsukihisa
    Shiraishi, Yoshimasa
    Takenaka, Tomoyoshi
    Yamaguchi, Masafumi
    Takenoyama, Mitsuhiro
    Ichinose, Yukito
    [J]. ANTICANCER RESEARCH, 2014, 34 (02) : 927 - 931